ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last2,181 to 2,200 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Losartan 50 mg vs Losartan 150 mg: serious adverse events691 of 1,913

710 of 1,921

-0.8 points

-3.9 to 2.2

3,834NCT00090259

Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)

Good School Toolkit vs Control: Physical Violence From School Staff595 of 1,921

924 of 1,899

-17.7 points

-20.7 to -14.6

3,820NCT01678846

Good Schools Study

Matched Treated: Absence Eligibility vs Matched Untreated: Absence Eligibility: Number of Participants With Presence of Any Absence Records: Matched Participants1,255 of 1,909

1,331 of 1,909

-4.0 points

-6.9 to -1.0

3,818NCT07072793

A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe

Daprodustat vs Darbepoetin Alfa: Number of Participants With at Least One BP Exacerbation Event During Study939 of 1,919

1,012 of 1,884

-4.8 points

-7.9 to -1.6

3,803NCT02876835

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

Vaccine vs Placebo: Number of Participants With Wild Type-4 Febrile Adenovirus (ADV) Acute Respiratory Disease (ARD) -- PP Cohort1 of 2,855

47 of 945

-4.9 points

-6.5 to -3.7

3,800NCT00382408

A Clinical Trial to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001

Donning Non-Sterile Gloves Without Hand Hygiene vs Hand Hygiene Before Donning Non-Sterile Gloves: Number of Participants With Composite Compliance With Expected Infection Prevention Practices Upon Entry to Contact Precaution-patient Rooms1,297 of 1,491

954 of 2,299

45.5 points

42.8 to 48.1

3,790NCT03119389

Direct Gloving Strategy: A Cluster-randomized Trial

Donning Non-Sterile Gloves Without Hand Hygiene vs Hand Hygiene Before Donning Non-Sterile Gloves: Proportion of Healthcare Worker Who Use Glove on Entry Into Contact Precaution Rooms1,297 of 1,491

1,530 of 2,299

20.4 points

17.8 to 23.0

3,790NCT03119389

Direct Gloving Strategy: A Cluster-randomized Trial

Intervention Group vs Wait List Control Group: Initiation of the HPV Vaccine 2-dose Series.1,723 of 2,151

1,219 of 1,615

4.6 points

1.9 to 7.3

3,766NCT04180462

Increasing Optimal Use of HPV Vaccination in Primary Care

Intervention Group vs Wait List Control Group: Completion of the HPV Vaccine 2-dose Series.1,135 of 2,151

809 of 1,615

2.7 points

-0.6 to 5.9

3,766NCT04180462

Increasing Optimal Use of HPV Vaccination in Primary Care

Pre-Intervention: Patients Diagnosed With Conditions of Interest During Study Period vs Post-Intervention: Patients Diagnosed With Conditions of Interest During Study Period: Guideline-concordant Decision to Not Prescribe Antibiotics for Adult Pharyngitis1,432 of 1,432

2,312 of 2,317

0.2 points

-0.1 to 0.5

3,749NCT06027593

Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions

Cervarix Group vs Placebo Group: Number of Subjects With Unsolicited Adverse Events for Subjects Seronegative and DNA Negative for Both HPV-16 and HPV-18 at Baseline497 of 1,892

468 of 1,843

0.9 points

-1.9 to 3.7

3,735NCT00779766

Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects

Cervarix Group vs Placebo Group: Number of Subjects With Medically Significant Conditions Regardless of Causal Relationship to Vaccination and Intensity for Subjects Seronegative and DNA Negative for Both HPV-16 and HPV-18 at Baseline122 of 1,892

110 of 1,843

0.5 points

-1.1 to 2.0

3,735NCT00779766

Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects

10 mg Empagliflozin vs Placebo: deaths from any cause249 of 1,863

266 of 1,867

-0.9 points

-3.1 to 1.3

3,730NCT03057977

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

10 mg Empagliflozin vs Placebo: serious adverse events772 of 1,863

896 of 1,863

-6.7 points

-9.8 to -3.5

3,726NCT03057977

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

Three-chambered Bag (3CB) vs Hospital-Compounded Bag (HCB): Treatment With Antimicrobials During PN831 of 2,753

370 of 970

-8.0 points

-11.5 to -4.5

3,723NCT03284398

Three-Chamber Bags Retrospective Study in Spain

Three-Chambered Bag (3CB) vs Hospital-compounded Bag (HCB): Renal Replacement Therapy78 of 2,753

89 of 970

-6.3 points

-8.4 to -4.5

3,723NCT03284398

Three-Chamber Bags Retrospective Study in Spain

Three-Chambered Bag (3CB) vs Hospital-compounded Bag (HCB): Use of Mechanical Ventilation410 of 2,753

299 of 970

-15.9 points

-19.2 to -12.8

3,723NCT03284398

Three-Chamber Bags Retrospective Study in Spain

Three-Chambered Bag (3CB) vs Hospital-Compounded Bag (HCB): Sepsis During PN431 of 2,753

228 of 970

-7.8 points

-10.9 to -4.9

3,723NCT03284398

Three-Chamber Bags Retrospective Study in Spain

Three-Chambered Bag vs Hospital-compounded Bag: Percentage of Patients Presenting With a Confirmed Microbial Blood Stream Infection During Treatment With PN for Each Group (3CB vs HCB)127 of 2,753

106 of 970

-6.3 points

-8.6 to -4.3

3,723NCT03284398

Three-Chamber Bags Retrospective Study in Spain

Three-Chambered Bag (3CB) vs Hospital-compounded Bag (HCB): Use of Vasopressor Treatment410 of 2,753

291 of 970

-15.1 points

-18.3 to -12.0

3,723NCT03284398

Three-Chamber Bags Retrospective Study in Spain

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=110"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=110

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00090259-sae",
        "title": "Losartan 50 mg vs Losartan 150 mg: serious adverse events",
        "summary": "691 of 1913 against 710 of 1921; risk difference -0.8 points, 95% interval -3.9 to 2.2; NCT00090259, Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)",
        "record": "/library/comparisons/NCT00090259-sae",
        "nct_id": "NCT00090259",
        "kind": "serious-adverse-events",
        "participants": 3834,
        "risk_difference": {
          "value": -0.008386412265131371,
          "lower": -0.03883242426312185,
          "upper": 0.022083845915999968
        },
        "group_1": "691 of 1,913",
        "group_2": "710 of 1,921",
        "difference": "-0.8 points",
        "interval": "-3.9 to 2.2",
        "trial_title": "Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)"
      },
      {
        "id": "NCT01678846-392ea22b",
        "title": "Good School Toolkit vs Control: Physical Violence From School Staff",
        "summary": "595 of 1921 against 924 of 1899; risk difference -17.7 points, 95% interval -20.7 to -14.6; NCT01678846, Good Schools Study",
        "record": "/library/comparisons/NCT01678846-392ea22b",
        "nct_id": "NCT01678846",
        "kind": "outcome",
        "participants": 3820,
        "risk_difference": {
          "value": -0.17683736666247257,
          "lower": -0.20711670810520494,
          "upper": -0.14608378154577525
        },
        "group_1": "595 of 1,921",
        "group_2": "924 of 1,899",
        "difference": "-17.7 points",
        "interval": "-20.7 to -14.6",
        "trial_title": "Good Schools Study"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=111",
  "request_id": "bt5Yz4PB6CpXG0ie"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?